Cocktail e Matla ea Lithethefatsi tsa Biologic bakeng sa Thibelo ea Tšoaetso e Tloaelehileng ea Sepetlele

Kalafo ea lithibela-mafu hangata e atleha maemong a pele a CDI. Leha ho le joalo, 20% -40% ea bakuli ba tla utloa bohloko hape, 'me monyetla oa liketsahalo tse eketsehileng bakeng sa bakuli bana o feta 40%. Mekhoa e teng hona joale ea ho thibela CDI e sitisoa ke litšenyehelo tse phahameng, ho beleha ho sa sebetseng hantle (maemong a mangata ho hloka tsamaiso ea I.V. bakeng sa li-antibodies tsa setso kapa prep ea mala kapa enema bakeng sa transplant ea mantle a microbiota).

Lumen Bioscience, k'hamphani ea kliniki ea biopharmaceutical e hlahisang meriana ea likokoana-hloko bakeng sa mafu a atileng haholo, kajeno e phatlalalitse lipatlisiso tse hlalosang LMN-201, e leng cocktail ea ho etsa lipatlisiso ka molomo ho thibela tšoaetso ea C. difficile (CDI). LMN-201 e kopanya liprotheine tse 'nè tsa phekolo-tse entsoeng le ho fanoa ka microorganism e jeoang spirulina-tse sebetsang ka bonngoe ho fokotsa bobeli ba baktheria ea C. difficile le chefo e bakang ho se sebetse ha eona.             

Pampiri e ncha e reng, "Ho sebelisa antibody synergy ho boenjiniere ba cocktail e phahameng ea potency biologic khahlanong le C. difficile," e ile ea kenngoa ho "preprint server" bioRxiv e emetse tlhahlobo ea lithaka. E hlalosa lintlha tsa in vitro le in vivo tse bonts'ang hore LMN-201 e sebetsa haholo ho thibela CDI mefuteng e 'meli e ikemetseng ea CDI. Patlisiso e entsoe ke bo-ramahlale ba Lumen hammoho le bafuputsi ba etelletseng pele lefapheng la CDI lilaboratoring tse ikemetseng tsa lipatlisiso tse tšehelitsoeng ka karolo e 'ngoe ka lichelete tse tsoang ho NIH's National Institutes of Allergy and Infectious Diseases.

Pampiri e boetse e tlaleha tsoelo-pele ea bohlokoa mahlaleng a nts'etsopele ea li-antibody cocktail e ka thusang lithethefatsi tse matla ho feta tsa antibody nakong e tlang. Mosebetsi o bontša kamoo ho sebelisa litlhahlobo tse ngata tsa antibody synergy ho tataisa nts'etsopele ho ka matlafatsang matla a kalafo ea li-cocktail ka makhetlo a likete. Karolo ena ea lipatlisiso e na le litlamorao tse hlakileng bakeng sa lipheo tse ngata tsa mafu ho feta C. difficile feela, ho kenyeletsoa mananeo a ntlafatso ea pele ea Lumen ka lefu la ho ruruha ha mala le lefu la pelo.

"LMN-201 e theha paradigm e ncha bakeng sa li-cocktails tse sireletsehileng le tse matla haholo bakeng sa sepheo sa mafu ka har'a pampitšana ea GI," ho boletse Jim Roberts, mothehi-'moho le Lumen le Ofisiri e ka Sehloohong ea Saense. "Mokhoa ona o na le liphello tse kholo tsa ho phekola mathata a mang a GI-centric ka mekhoa e rarahaneng e kang Crohn's disease, ulcerative colitis, mafu a metabolic le lefu la celiac, moo mathata a tšoanang a matla le scalability a sitisitseng tsoelo-pele ea phekolo ea protheine e fanoang ka molomo."

Khamphani e boetse e phatlalalitse ho phetheloa ha Cohort 1 ea teko ea eona ea bongaka ea Pharmacokinetic ea Phase 1 ea LMN-201. Sepheo se ka sehloohong ke ho hlahloba kinetics ea ho qhibiliha ea li-capsules tsa enteric tse etselitsoeng ho lokolla liprotheine tsa phekolo ea LMN-201 pele kapa pele ho ileum ea ho qetela, moo C. difficile e thehoang ho bakuli ba bangata. Teko e fihletse pheletso ea eona ea mantlha bakeng sa Sehlopha sa 1, ho bonts'a hore li-capsules li ka fana ka LMN-201 ka katleho moo ho hlokahalang. Kamora ho phethoa ha Cohort 2 ea netefatso ea thuto mathoasong a selemo se tlang, tlhahlobo e felletseng e tla phethoa le ho phatlalatsoa koranteng e hlahlobiloeng ke lithaka.